Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

@article{Moertel1991TreatmentON,
  title={Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms},
  author={Charles G. Moertel and Larry K. Kvols and Michael J. O’connell and Joseph Rubin},
  journal={Cancer},
  year={1991},
  volume={68}
}
Forty‐five patients with metastatic neuroendocrine tumors were treated with a regimen of etoposide 130 mg/m2/d for 3 days plus cisplatin 45 mg/m2/d on days 2 and 3. Both drugs were given by continuous intravenous infusion. Among 27 patients with well‐differentiated carcinoid tumors or islet cell carcinomas, only two partial objective tumor regressions were observed (7%). Among 18 patients prospectively classified as having anaplastic neuroendocrine carcinomas, however, there were nine partial… 
A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors
TLDR
It is concluded that while the combination of irinotecan and cisplatin may have activity in aggressive neuro endocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors.
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
TLDR
It is confirmed that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination, however, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed.
The treatment of undifferentiated neuroendocrine tumors.
First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
TLDR
Platinum-based chemotherapy showed good efficacy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma and those with Ki67 ≤55%, positive Gallium-68 positron emission tomography/computerized tomography and BMI <25 had a better prognosis.
Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
TLDR
Efficacy was insufficient in patients who had carcinoid tumors but the combination of dacarbazine with fluorouracil and leucovorin could be an effective regimen for the treatment of neuroendocrine tumors of unknown primary site.
Experience in treatment of metastatic pulmonary carcinoid tumors.
TLDR
The results of systemic antitumoral treatment of pulmonary carcinoids with distant metastases are generally discouraging, and Chemotherapy with cisplatinum + etoposide, or doxorubicin combined with streptozotocin or paclitaxel may be of value.
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma
TLDR
Gastric PNEC patients with distant metastasis had poor outcomes, andimens containing cisplatin plus irinotecan produced a good response in gastric PNs, a retrospective review of histopathologically confirmed NETs of the stomach.
Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas
TLDR
This retrospective cohort of advanced extrapulmonary PDNEC patients suggests that the IP combination is feasible and resulted in similar response rate and median survival to other treatments previously reported.
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
TLDR
FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile and Grade and mitotic index are the best predictors of response.
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
TLDR
The authors' polychemotherapy regimen is effective, with long duration, and is well tolerated both for gastroenteropancreatic and lung NETs, as well as for tumours with a more aggressive clinical behaviour.
...
...

References

SHOWING 1-4 OF 4 REFERENCES
Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
TLDR
Recognition of these tumors broadens the spectrum of neuroendocrine neoplasia, and also identifies a distinct subset of patients with poorly differentiated carcinoma of unknown primary site.
A Phase I‐II Study of Sequential Infusion VP‐16 and Cisplatin Therapy in Advanced Lung Cancer
Although the etoposide (VP-16) and cisplatin combination has shown therapeutic activity in lung cancer, human results to date have not matched the expectation of synergism raised by animal model
Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation.
TLDR
These tumors were, as a group, aggressive, with eight patients dead within 12 months of diagnosis and Median survival was 7 months, with three patients alive at 2, 38, and 68 months, respectively.
Carcinoids: The association of histologic growth pattern and survival
TLDR
Histologic growth patterns of 138 carcinoids collected from an Eastern Cooperative Oncology Group carcinoid advanced stage disease chemotherapy investigation are studied and recommended as a stratification factor in future studies of this disease.